SecBot SecBot
Insider Cluster (2 insiders) ·Filed May 1, 2026

CORT

CORCEPT THERAPEUTICS INC
NEUTRAL
Impact 3/10
Horizondays Processed6mo ago
Insider cluster: 2 insiders, $3.0M total
Actionable Insight • Neutral

Monitor upcoming Q2 earnings for profitability recovery as guided, and track early Lifyorli sales trajectory. Insider sales are minor and do not warrant action, but any acceleration in selling by C-suite would be a watch item.

DirectionNeutral
Confidencehigh
Horizondays

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$51.42
T+0 close · Apr 30, 2026 · via day close
Latest settled
+83.18%
T+60 · $94.19
Vs SPY
+80.11%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 1 $51.42entry
  2. T+1 · 7mo ago +0.35%α +0.69% · $51.60
  3. T+5 · 6mo ago −0.72%α −3.07% · $51.05
  4. T+20 · 6mo ago +36.99%α +31.70% · $70.44
  5. T+60 · 4mo ago +83.18%α +80.11% · $94.19
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Corcept Therapeutics' CEO and CDO sold $3.04M in open-market shares within a week of the Q1 earnings release. The trades represent only ~0.05% of market cap and are likely routine portfolio management, not a bearish signal. Q1 revenue grew 4.9% YoY to $164.9M, but the company reported a net loss of $31.8M vs net income of $20.5M in the prior year, driven by increased spending on the Lifyorli launch.

Key Financial Metrics

Direction
selling
Total Value
$3.0M
Insiders
2

Key Facts

  • CEO Belanoff sold 40,000 shares at ~$50.10 for $2.00M on May 1, 2026.
  • CDO Guyer sold 20,000 shares at ~$51.83 for $1.04M on May 5, 2026 (also exercised options with no cash impact).
  • Total insider sales of $3.04M represent ~0.054% of $5.6B market cap.
  • Q1 2026 revenue rose 4.9% YoY to $164.9M; net loss of $31.8M vs net income of $20.5M in Q1 2025.
  • 2026 revenue guidance raised to $950M-$1,050M; Lifyorli (relacorilant) approved by FDA for ovarian cancer in March 2026.

Financial Impact

Insider selling of $3.04M is negligible relative to $5.6B market cap.

revenuenet incomecash and investments

Risk Factors

  • Delays in relacorilant NDA for Cushing's syndrome or regulatory setbacks.
  • Competition in ovarian cancer and Cushing's syndrome markets.
  • Failure to return to profitability as guided in Q2 2026.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
75% bullish (12 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-CORT-1778185862573

Track record

36 reports on CORT

Performance horizon

8 of 9 bullish or bearish reports moved the stock their way by T+20. Best: +63.06% at T+60 after the Feb 24, 2026 report. 10 of 11 went positive at some point.

Filters
  1. Nov 13, 20263d ago Insider Cluster Neutral 2/10 Entry $73.87 Now $69.22 −6.29% settles Dec 15
  2. Nov 10, 20266d ago 144 Neutral 2/10 Entry $74.53 Now $69.22 −7.12% settles Dec 10
  3. Nov 4, 202612d ago Insider Cluster Neutral 2/10 Entry $71.63 Now $69.22 −3.36% settles Dec 4
  4. Nov 3, 202613d ago 8-K Bullish 6/10 Entry $79.22 Now $69.22 −12.62% settles Dec 3
  5. Nov 2, 202614d ago Institutional Cluster Bearish 4/10 Entry $81.93 Now $69.22 +15.51% settles Dec 2
  6. Oct 27, 202620d ago SC 13G/A Neutral 3/10 Entry $86.28 Now $69.22 −19.77% settles Nov 25
  7. Oct 5, 20266w ago Insider Cluster Neutral 3/10 Entry $119.57 to $81.93 Now $69.22 −42.11% ▼ −31.48% −28.30% vs SPY
  8. Sep 23, 20267w ago 8-K Neutral 3/10 Entry $112.94 to $116.28 Now $69.22 −38.71% ▲ +2.96% +2.27% vs SPY
  9. Sep 16, 20268w ago Insider Cluster Bearish 4/10 Entry $114.86 to $113.37 Now $69.22 +39.74% ▲ +1.30% +2.50% vs SPY
  10. Sep 16, 20268w ago Insider Cluster Bearish 4/10 Entry $114.86 to $113.37 Now $69.22 +39.74% ▲ +1.30% +2.75% vs SPY
Showing 10 of 36

US Market Status

Market Closed · Opens Wed (11h 38m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 7, 2026